Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Lucitanib for secondary hemophagocytic lymphohistiocytosis (phase 2, single-arm)
ChiCTR2000041490Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and lucitanib in haemophagocytic lymphohistiocytosis (HLH), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Overall response rate and Mortality. Started Jun 2020; status: recruiting.
02
Drugs
tislelizumablucitanib
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on ChiCTR2000041490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041490.